Novo’ Nordisk’s drug to cut kidney disease advance in diabetics gets nod
Novo Nordisk’s medicine has been approved by the US drug regulator for reducing the risk of kidney failure and death due to cardiovascular.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Novo Nordisk’s medicine has been approved by the US drug regulator for reducing the risk of kidney failure and death due to cardiovascular.
Novo Nordisk A/S, a Danish pharmaceutical company, has expanded its agreement with US-based Valo Health Inc., almost to double the number of drugs.
HQ Team December 13, 2024: Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).
Bharti Jayshankar December 5, 2024: Dark chocolate is a healthy indulgence allowed even for diabetics, with research supporting its benefits. Studies suggest that.
HQ Team November 9, 2024: A recent study indicates that rosuvastatin is associated with a slightly reduced risk of all-cause mortality and major.
Danish multinational pharmaceutical company Novo Nordisk’s end-stage trial in patients with fatty liver disease saw reduced liver scarring (fibrosis) and its resolution without.
HQ Team October 15, 2024: A recent study presented at the United European Gastroenterology Week congress in Vienna unveiled a procedure that could.
Insulet Corporation, a tubeless insulin pump maker, got clearance from the US Food and Drug Administration to add diabetes type 2 adult patients.
AstraZeneca’s oral drug to treat type-2 diabetes in patients aged 10 years and above has got approval from the US drug regulator, according.
HQ Team March 6, 2024: Novo Nordisk’s diabetes drug Ozempic delayed the progression of kidney disease and cardiovascular and kidney deaths in 24%.